Functional Neuromodulation Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Functional Neuromodulation Ltd.
At NANS, Boston Scientific presented results of the COMBO study, announced a partnership with IBM Research on digital health, and reported strong US growth in its deep brain stimulation business. Boston's C suite sees rebound for lagging neuromodulation business in 2020.
FDA issued a draft guidance to help device-makers conduct clinical trials for products designed to slow the progress of neurological conditions. One challenge highlighted by the agency is that changes to biomarkers measured in a study may not line up easily with disease progression.
The US neurostimulation technology market will grow nearly 46% over the next five years, according to a new report from Medtech Insight.
The transcatheter aortic valve PARTNER II study, several stent trials, and studies looking at diagnostic tools and neurological devices dominated the top ten trials by total payment to clinical investigators in 2014, according to an analysis of CMS' Open Payments database.
- Implantable Devices
- Surgical Equipment & Devices
Drug Discovery Tools
- Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.